Stock Track | Autolus Therapeutics Soars 9.7% in Pre-Market on Analyst Upgrade and FDA Approval Prospects

Stock Track

2024-11-18

Autolus Therapeutics PLC (AUTL) saw its stock soar 9.7% in pre-market trading on Monday, following positive analyst coverage and anticipation of FDA approval for one of its drug candidates.

Goldman Sachs upgraded Autolus Therapeutics to a "Buy" rating from "Neutral" and raised its price target to $7.60, citing the potential approval of the company's lead drug candidate Aucatzyl. Analyst Rajan Sharma noted that FDA approval of Aucatzyl would de-risk Autolus' platform and could lead to significant upside for the stock.

Additionally, analysts polled by Capital IQ have an average "Buy" rating on Autolus Therapeutics, with price targets ranging from $7 to $13, indicating further upside potential if the company's pipeline progresses favorably.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1148503177"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148503177\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1148503177?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-18 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148503177","market":"hk","top_or_hot":-1,"title":"Stock Track | Autolus Therapeutics Soars 9.7% in Pre-Market on Analyst Upgrade and FDA Approval Prospects","media":"Stock Track","content":"<p>Autolus Therapeutics PLC (AUTL) saw its stock soar 9.7% in pre-market trading on Monday, following positive analyst coverage and anticipation of FDA approval for one of its drug candidates.</p>\n\n<p>Goldman Sachs upgraded Autolus Therapeutics to a \"Buy\" rating from \"Neutral\" and raised its price target to $7.60, citing the potential approval of the company's lead drug candidate Aucatzyl. Analyst Rajan Sharma noted that FDA approval of Aucatzyl would de-risk Autolus' platform and could lead to significant upside for the stock.</p>\n\n<p>Additionally, analysts polled by Capital IQ have an average \"Buy\" rating on Autolus Therapeutics, with price targets ranging from $7 to $13, indicating further upside potential if the company's pipeline progresses favorably.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Autolus Therapeutics Soars 9.7% in Pre-Market on Analyst Upgrade and FDA Approval Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Autolus Therapeutics Soars 9.7% in Pre-Market on Analyst Upgrade and FDA Approval Prospects\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-11-18 21:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Autolus Therapeutics PLC (AUTL) saw its stock soar 9.7% in pre-market trading on Monday, following positive analyst coverage and anticipation of FDA approval for one of its drug candidates.</p>\n\n<p>Goldman Sachs upgraded Autolus Therapeutics to a \"Buy\" rating from \"Neutral\" and raised its price target to $7.60, citing the potential approval of the company's lead drug candidate Aucatzyl. Analyst Rajan Sharma noted that FDA approval of Aucatzyl would de-risk Autolus' platform and could lead to significant upside for the stock.</p>\n\n<p>Additionally, analysts polled by Capital IQ have an average \"Buy\" rating on Autolus Therapeutics, with price targets ranging from $7 to $13, indicating further upside potential if the company's pipeline progresses favorably.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AUTL","symbol_name":"Autolus Therapeutics PLC","start_time":0,"source_url":"","article_id":"1148503177","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148503177","pubTimestamp":1731934934,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Autolus Therapeutics PLC  saw its stock soar 9.7% in pre-market trading on Monday, following positive analyst coverage and anticipation of FDA approval for one of its drug candidates.Goldman Sachs upgraded Autolus Therapeutics to a \"Buy\" rating from \"Neutral\" and raised its price target to $7.60, citing the potential approval of the company's lead drug candidate Aucatzyl. Analyst Rajan Sharma noted that FDA approval of Aucatzyl would de-risk Autolus' platform and could lead to significant upside","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AUTL":"Autolus Therapeutics PLC"},"translate_title":"由于分析师升级和FDA批准前景，股票跟踪Autolus Therapeutics盘前飙升9.7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUTL":1},"content_text":"Autolus Therapeutics PLC (AUTL) saw its stock soar 9.7% in pre-market trading on Monday, following positive analyst coverage and anticipation of FDA approval for one of its drug candidates.\nGoldman Sachs upgraded Autolus Therapeutics to a \"Buy\" rating from \"Neutral\" and raised its price target to $7.60, citing the potential approval of the company's lead drug candidate Aucatzyl. Analyst Rajan Sharma noted that FDA approval of Aucatzyl would de-risk Autolus' platform and could lead to significant upside for the stock.\nAdditionally, analysts polled by Capital IQ have an average \"Buy\" rating on Autolus Therapeutics, with price targets ranging from $7 to $13, indicating further upside potential if the company's pipeline progresses favorably.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}